Pfizer Inc. $PFE Shares Sold by Armstrong Henry H Associates Inc.

Armstrong Henry H Associates Inc. cut its stake in Pfizer Inc. (NYSE:PFE) by 3.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 15,394 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Armstrong Henry H Associates Inc.’s holdings in Pfizer were worth $373,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Trust Co of the South boosted its position in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares during the last quarter. William B. Walkup & Associates Inc. lifted its position in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after buying an additional 454 shares in the last quarter. Members Trust Co lifted its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares in the last quarter. Sutton Place Investors LLC lifted its position in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 472 shares in the last quarter. Finally, MSH Capital Advisors LLC lifted its position in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 485 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 3.8%

NYSE PFE opened at $23.91 on Friday. The company’s fifty day simple moving average is $24.79 and its 200-day simple moving average is $24.28. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is 91.49%.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.